Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.12 AUD | +1.36% |
|
+12.00% | +261.29% |
02/07 | Mesoblast to File Biological License Application with US FDA for Cellular Therapy | MT |
01/07 | Mesoblast to File Biologics License Application for Ryoncil | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+261.29% | 85Cr | |
+19.47% | 4.53TCr | |
+42.78% | 4.04TCr | |
-9.54% | 3.79TCr | |
+31.38% | 3.18TCr | |
-7.79% | 2.77TCr | |
+13.56% | 2.65TCr | |
+43.46% | 1.4TCr | |
+32.04% | 1.24TCr | |
-6.91% | 1.13TCr |
- Stock Market
- Equities
- MSB Stock
- News Mesoblast Limited
- Transcript : Mesoblast Limited, Q4 2022 Earnings Call, Aug 30, 2022